{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:04:12Z","timestamp":1779109452506,"version":"3.51.4"},"reference-count":60,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T00:00:00Z","timestamp":1688860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>In recent years, there has been a noticeable development in oncological treatment, including chemotherapy and biological treatment. Despite their significant effectiveness, they are not free from side effects, such as allergic and dermatological reactions. These reactions can vary in severity and outcome, including potential death. Examples, among others, are type I-IV hypersensitivity reactions of various origins and skin reactions including rashes, itching and redness, but also severe cutaneous syndromes. Due to the therapy used, these may include Stevens\u2013Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, drug-induced hypersensitivity syndrome and acute generalized exanthematous pustulosis. In some cases, it is necessary to interrupt therapy, which may result in a poorer outcome and shorten the patient\u2019s survival. This paper reviews various types of research documents published since 2016. It aims to systematize the latest knowledge and highlight the need for further research into ways to avoid adverse reactions.<\/jats:p>","DOI":"10.3390\/ijms241411257","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:35:21Z","timestamp":1688949321000},"page":"11257","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune Reactions in Major Types of Oncological Treatment"],"prefix":"10.3390","volume":"24","author":[{"given":"Patrycja","family":"Kozubek","sequence":"first","affiliation":[{"name":"Student Scientific Group of Adult Allergology, 50-369 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Wo\u0142oszczak","sequence":"additional","affiliation":[{"name":"Student Scientific Group of Adult Allergology, 50-369 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7218-2961","authenticated-orcid":false,"given":"Krzysztof","family":"Gomu\u0142ka","sequence":"additional","affiliation":[{"name":"Clinical Department of Internal Medicine, Pneumology and Allergology, Wroclaw Medical University, 50-369 Wroc\u0142aw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mori, F., Saretta, F., Bianchi, A., Crisafulli, G., Caimmi, S., Liotti, L., Bottau, P., Franceschini, F., Paglialunga, C., and Ricci, G. (2020). Hypersensitivity Reactions to Monoclonal Antibodies in Children. Medicina, 56.","DOI":"10.3390\/medicina56050232"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.mcna.2019.09.003","article-title":"Drug Hypersensitivity Reactions","volume":"104","author":"Dykewicz","year":"2020","journal-title":"Med. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/all.14984","article-title":"Hypersensitivity Reactions to Biologicals: An EAACI Position Paper","volume":"77","author":"Bavbek","year":"2022","journal-title":"Allergy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2018.02.018","article-title":"Hypersensitivity Reactions to Therapeutic Monoclonal Antibodies: Phenotypes and Endotypes","volume":"142","author":"Isabwe","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am. J. Clin. Derm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/CMAR.S163391","article-title":"Severe Cutaneous Adverse Reactions Induced by Targeted Anticancer Therapies and Immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Park, J.H., Kim, M.Y., Choi, I.S., Kim, J.W., Kim, J.W., Lee, K.W., and Kim, J.S. (2022). Identification of Immune-Related Mechanisms of Cetuximab Induced Skin Toxicity in Colorectal Cancer Patients. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0276497"},{"key":"ref_8","first-page":"1","article-title":"Cutaneous Adverse Events and Quality of Life in Outpatients Receiving Anticancer Agents: Results from an Observational, Cross-Sectional Study","volume":"9","author":"Oh","year":"2020","journal-title":"Drugs Context."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/ACI.0000000000000548","article-title":"Cutaneous Drug Hypersensitivity: Developments and Controversies","volume":"19","author":"Brockow","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s15007-020-2550-1","article-title":"Hypersensitivity Reactions to Biologics (Part I): Allergy as an Important Differential Diagnosis in Complex Immune-Derived Adverse Events*","volume":"29","author":"Wedi","year":"2020","journal-title":"Allergo J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101580","DOI":"10.1016\/j.isci.2020.101580","article-title":"Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade","volume":"23","author":"Hu","year":"2020","journal-title":"iScience"},{"key":"ref_12","first-page":"516","article-title":"Cutaneous Toxicity in Oncologic Patients Receiving Epidermal Growth Factor Receptor Inhibitors","volume":"47","author":"Popa","year":"2021","journal-title":"Curr. Health Sci. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3892\/etm.2021.10381","article-title":"Hypersensitivity Reactions to Monoclonal Antibodies: Classification and Treatment Approach (Review)","volume":"22","author":"Pintea","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100553","DOI":"10.1016\/j.waojou.2021.100553","article-title":"Nationwide Pharmacovigilance Data for Cetuximab-Induced Anaphylaxis and Predictive Model Validation Using Prospective Specific IgE Detection","volume":"14","author":"Park","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.det.2018.02.010","article-title":"Pruritus Associated with Targeted Anticancer Therapies and Their","volume":"36","author":"Wu","year":"2018","journal-title":"Derm. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.anai.2021.03.008","article-title":"Hypersensitivity Reactions and Anaphylaxis to Checkpoint Inhibitor-Monoclonal Antibodies and Desensitization","volume":"126","author":"Labella","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous Adverse Events Caused by Immune Checkpoint Inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J. Am. Acad. Derm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic Toxicities to Immune Checkpoint Inhibitor Therapy: A Review of Histopathologic Features","volume":"83","author":"Ellis","year":"2020","journal-title":"J. Am. Acad. Derm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"605941","DOI":"10.3389\/fonc.2021.605941","article-title":"Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers","volume":"11","author":"Espinosa","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40257-020-00539-7","article-title":"BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors","volume":"21","author":"Wang","year":"2020","journal-title":"Am. J. Clin. Derm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1848058","DOI":"10.1080\/2162402X.2020.1848058","article-title":"Skin Inflammatory Response and Efficacy of Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer (CUTACETUX)","volume":"9","author":"Tougeron","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_22","first-page":"7595706","article-title":"Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies","volume":"2019","author":"Vijayagopal","year":"2019","journal-title":"Autoimmune Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.clindermatol.2020.06.007","article-title":"Adverse Cutaneous Reactions to Chemotherapeutic Drugs","volume":"38","author":"Haynes","year":"2020","journal-title":"Clin. Derm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1002\/cam4.4252","article-title":"Severe Anaphylaxis Caused by Intravenous Anti-cancer Drugs","volume":"10","author":"Horita","year":"2021","journal-title":"Cancer Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jcpt.12645","article-title":"Retrospective Study of Hypersensitivity Reactions to Chemotherapeutic Agents in a Thoracic Oncology Service","volume":"43","author":"Capelle","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/ijgc-2018-000072","article-title":"A Cohort Study of Hypersensitivity Reaction in Patients with Epithelial Ovarian Cancer Treated with Carboplatin","volume":"29","author":"Sun","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity Reactions to Platinum Agents and Taxanes","volume":"62","author":"Tsao","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.tjog.2021.07.018","article-title":"Drug Fever Induced by Carboplatin-Based Regimens: Higher Incidence in a Women\u2019s Hospital","volume":"60","author":"Zhang","year":"2021","journal-title":"Taiwan. J. Obs. Gynecol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2016.10.023","article-title":"Cisplatin Can Be Safely Administered to Ovarian Cancer Patients with Hypersensitivity to Carboplatin","volume":"144","author":"Bergamini","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jaip.2019.01.057","article-title":"Low Cross-Reactivity Between Cisplatin and Other Platinum Salts","volume":"7","author":"Pasteur","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/ijd.IJD_584_17","article-title":"Unusual and Interesting Adverse Cutaneous Drug Reactions","volume":"63","author":"Masatkar","year":"2018","journal-title":"Indian. J. Derm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.abd.2021.05.007","article-title":"Cutaneous Adverse Events to Systemic Antineoplastic Therapies: A Retrospective Study in a Public Oncologic Hospital","volume":"97","author":"Ceglio","year":"2022","journal-title":"Bras. Derm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fimmu.2019.00414","article-title":"Insights into the Pathogenesis of Sweet\u2019s Syndrome","volume":"10","author":"Heath","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40257-022-00673-4","article-title":"New Practical Aspects of Sweet Syndrome","volume":"23","author":"Joshi","year":"2022","journal-title":"Am. J. Clin. Derm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3389\/fimmu.2017.01472","article-title":"Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations","volume":"8","author":"Castells","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3349\/ymj.2019.60.2.119","article-title":"Desensitization for Allergic Reactions to Chemotherapy","volume":"60","author":"Hong","year":"2019","journal-title":"Yonsei Med. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.23822\/EurAnnACI.1764-1489.207","article-title":"Key Elements in Hypersensitivity Reactions to Chemotherapy: Experience with Rapid Drug Desensitization in Gynaecological Cancer in a Tertiary Hospital","volume":"54","author":"Cunha","year":"2022","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.18176\/jiaci.0712","article-title":"Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization","volume":"31","author":"Vega","year":"2021","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"de las Vecillas S\u00e1nchez, L., Alenazy, L.A., Garcia-Neuer, M., and Castells, M.C. (2017). Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18061316"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e12086","DOI":"10.1002\/clt2.12086","article-title":"Omalizumab for Successful Chemotherapy Desensitisation: What We Know so Far","volume":"11","author":"Bumbacea","year":"2021","journal-title":"Clin. Transl. Allergy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","article-title":"A Large Single-Hospital Experience Using Drug Provocation Testing and Rapid Drug Desensitization in Hypersensitivity to Antineoplastic and Biological Agents","volume":"7","author":"Gehlhaar","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1016\/j.jaip.2021.06.024","article-title":"One-Dilution Rapid Desensitization Protocol to Chemotherapeutic and Biological Agents: A Five-Year Experience","volume":"9","author":"Verdesoto","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s40521-018-0160-x","article-title":"Options in Hypersensitivity Reactions to Chemotherapeutics","volume":"5","author":"Pagani","year":"2018","journal-title":"Curr. Treat. Options Allergy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.jaip.2017.11.033","article-title":"Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol","volume":"6","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.31925\/farmacia.2021.3.3","article-title":"Platinum Hypersensitivity Reactions, a Focus on Desensitisation","volume":"69","author":"Havasi","year":"2021","journal-title":"Farmacia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.23822\/EurAnnACI.1764-1489.202","article-title":"Successful Desensitization with Chemotherapeutic Drugs: A Tertiary Care Center Experience","volume":"54","author":"Kaya","year":"2022","journal-title":"Eur. Ann. Allergy Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100640","DOI":"10.1016\/j.waojou.2022.100640","article-title":"Standards for Practical Intravenous Rapid Drug Desensitization & Delabeling: A WAO Committee Statement","volume":"15","author":"Broyles","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.18176\/jiaci.0171","article-title":"Chemotherapy in Mastocytosis: Administration Issues, Hypersensitivity, and Rapid Drug Desensitization","volume":"27","year":"2017","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jaip.2020.02.013","article-title":"Endophenotyping Oxaliplatin Hypersensitivity: Personalizing Desensitization to the Atypical Platin","volume":"8","author":"Silver","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/all.14644","article-title":"Interleukin-6: A Novel Biomarker for Monoclonal Antibody and Chemotherapy-Associated Hypersensitivity Confirms a Cytokine Release Syndrome Phenotype-Endotype Association","volume":"76","author":"Jakubovic","year":"2021","journal-title":"Allergy Eur. J. Allergy Clin. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40521-020-00238-y","article-title":"Importance of Diagnostics Prior to Desensitization in New Drug Hypersensitivity: Chemotherapeutics and Biologicals","volume":"7","author":"Lleonart","year":"2020","journal-title":"Curr. Treat. Options Allergy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/ejhpharm-2018-001746","article-title":"Current Situation of Carboplatin Desensitisation Protocols in the Hospitals of Spain","volume":"27","year":"2020","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"151132","DOI":"10.1016\/j.soncn.2021.151132","article-title":"Hypersensitivity and Chemotherapy Desensitization","volume":"37","author":"Lawry","year":"2021","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12016-016-8556-5","article-title":"Diagnoses and Management of Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: Reactions to Taxanes and Monoclonal Antibodies","volume":"54","author":"Castells","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1111\/all.14432","article-title":"Medical Algorithm: Diagnosis and Treatment of Drug Hypersensitivity Reactions to Biologicals","volume":"75","author":"Yang","year":"2020","journal-title":"Allergy"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11882-021-01014-x","article-title":"Drug Desensitizations for Chemotherapy: Safety and Efficacy in Preventing Anaphylaxis","volume":"21","author":"Caiado","year":"2021","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s40521-022-00312-7","article-title":"New Technical Aspects Used in the Management of Desensitization to Antineoplastic Drugs","volume":"9","year":"2022","journal-title":"Curr. Treat. Options Allergy"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00432-018-2753-y","article-title":"Impact of Carboplatin Hypersensitivity and Desensitization on Patients with Recurrent Ovarian Cancer","volume":"144","author":"Altwerger","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"786822","DOI":"10.3389\/falgy.2022.786822","article-title":"Analysis of Breakthrough Reactions in 1143 Desensitization Procedures in a Single Tertiary Hospital Using a One-Bag Desensitization Protocol","volume":"3","author":"Kim","year":"2022","journal-title":"Front. Allergy"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","article-title":"Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies","volume":"4","author":"Sloane","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11257\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:09:23Z","timestamp":1760126963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,9]]},"references-count":60,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241411257"],"URL":"https:\/\/doi.org\/10.3390\/ijms241411257","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,9]]}}}